website promotion

[naijaname]

website advertising Final draft guidance from the health body suggested the drug should be made available provided it was sold to the NHS at a discount.
Dabrafenib, marketed by GlaxoSmithKline, targets a specific type of skin cancer which tests positive for the BRAF V600 mutation.
It kills cancer cells with the mutation, which can slow or stop the growth of the cancer.
Nice says the drug, also known as Tafinlar, should be made available for patients whose cancer tested positive for the mutation and had spread or could not be completely removed by surgery.
Prof Carole Longson, director for the centre for health technology evaluation at Nice, said: ’For a long time, the treatments available for skin cancer which has spread have been very limited.
’However, in recent years, a number of breakthrough treatments that can potentially significantly improve the prognosis for some people with malignant melanoma have become available.
’Drugs like dabrafenib are also thought to have very rapid positive effect for patients, even in those who are very unwell or bedridden. In some cases, it has enabled people to resume everyday activities.’advertising page.
Welcoming the news, Prof Paul Workman, interim chief executive of the Institute of Cancer Research, said: ’It’s great news that Nice has given the green light to use dabrafenib on the NHS
http://www.advertising-page.com

[thgk111]

"Nice says the drug, also known as Tafinlar, should be made available for patients whose cancer tested positive for the mutation and had spread or could not be completely removed by surgery."

I understand you mentioned, but will the patients fell convenient?

http://splittestmonkeyreviews.com/